IIARD International Institute of Academic Research and Development

JOURNAL OF BIOLOGY AND GENETIC RESEARCH (JBGR )

E-ISSN 2545-5710
P-ISSN 2695-222X
VOL. 10 NO. 2 2024
DOI: 10.56201/jbgr.v10.no2.2024.pg55.75

---

Relation of hypercytokinemia (cytokine storm) in viral respiratory SARS-COVID-2

Sura O. Yousif

---

Abstract

COVID-19 (coronavirus disease) has ravaged the world in a way that no previous pandemic in the past 50 years has. Since the epidemic, our knowledge of the illness has advanced significantly; multiorgan involvement has the greatest influence on disease prognosis. A rapidly developing respiratory condition that is characterized by severe inflammation and damage to the lungs, resulting in difficulty breathing and reduced oxygen levels in the blood, cardiac failure, liver failure, renal damage, shock, and multi-organ failure all increase morbidity and mortality. Hyperinflammatory response, characterized by elevated cytokine levels, may have a role in the pathophysiology of COVID-19 illness. One of the most prominent markers of C is 'cytokine storm syndrome.' The link between COVID-19 interferon-alpha, beta, and interferon-gamma tumor necrosis factor and significant cytokine families are examined in this study. We examine cytokine sources and biological roles while addressing numerous changes in immune response cellular components that correlate with cytokine levels. Lastly, we briefly explore future therapeutics aimed at modulating the cytokine storm.

keywords:

IL-6, IFN-?, TNF-?, SARS, coronavirus COVID-19.

---

References:

Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar
19;91(1):157-160.
doi: 10.23750/abm.v91i1.9397. PMID: 32191675; PMCID: PMC7569573.

Ronco C, Reis T, De Rosa S. 2020 Coronavirus epidemic and extracorporeal therapies in
intensive care: si vis pacem para bellum. Blood Purification 49, 255–258.
(doi:10.1159/000507039)

Huang C et al. 2020 Clinical features of patients infected with 2019 novel coronavirus in
Wuhan, China. The Lancet 395, 497–506. (doi:10.1016/ S0140-6736(20)30183-5)

Zhou F et al. 2020 Clinical course and risk factors for mortality of adult inpatients with
COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062.
(doi:10.1016/S0140-6736(20) 30566-3)

Hu H, Ma F, Wei X, Fang Y. 2020 Coronavirus fulminant myocarditis saved with
glucocorticoid and human immunoglobulin. Eur. Heart J. 16, ehaa190.
(doi:10.1093/eurheartj/ehaa190)

Ruan Q, Yang K, Wang W, Jiang L, Song J. 2020 Clinical predictors of mortality due to
COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care
Med. 46, 846–848. (doi:10.1007/s00134-020-05991-x)

Bikdeli B Madhavan MV Jimenez D Chuich T Dreyfus I COVID-19 and thrombotic or
thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up.
Journal of the American College of Cardiology. 2020;75:2950–2973. [PMC free article]
[PubMed] [Google Scholar]

Wu C et al. 2020 Risk factors associated with acute respiratory distress syndrome and death
in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med.
180, 934–943. (doi:10.1001/jamainternmed.2020.0994)

World Health Organization. Coronavirus disease (COVID-2019) situation reports. 2020.
https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
Accessed April 9, 2020.

Peng PWH, Ho P-L, Hota SS. 2020 Outbreak of a new coronavirus: what anaesthetists
should know. Br. J. Anaesth. 124, 497–501. (doi:10.1016/j.bja. 2020.02.008)

Centers for Disease Control and Prevention. People Who Are at Higher Risk for Severe
Illness. 2020; https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-
higher-risk.html. Accessed April 8,2020.

Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7).
Chin Med J (Engl). 2020 May 5;133(9):1087-1095. doi: 10.1097/CM9.0000000000000819.
PMID: 32358325; PMCID: PMC7213636.

Poston JT, Patel BK, Davis AM. 2020 Management of critically ill adults with COVID-
JAMA. 323, 1839–1841. (doi:10.1001/jama.2020.4914)

Li M.-Y., Li L, Zhang Y, Wang X.-S. 2020 Expression of the SARS-CoV-2 cell receptor
gene ACE2 in a wide variety of human tissues. Infectious Dis. Poverty 9, 45.
(doi:10.1186/s40249- 020-00662-x)

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. 2004 Tissue
distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in
understanding SARS pathogenesis. J. Pathol. 203, 631–637. (doi:10. 1002/path.1570)

Uhlen M et al. 2015 Proteomics. Tissue-based map of the human proteome. Science 347,
(doi:10.1126/science.1260419)

Goulter AB, Goddard MJ, Allen JC, Clark KL. 2004 ACE2 gene expression is up-regulated
in the human failing heart. BMC Med. 2, 19. (doi:10.1186/1741- 7015-2-19)
Danilczyk U, Penninger JM. 2006 Angiotensinconverting enzyme II in the heart and the
kidney. Circul. Res. 98, 463–471. (doi:10.1161/01.RES. 0000205761.22353.5f)

Clark IA, Virelizier JL, Carswell EA, Wood PR. 1981 Possible importance of macrophage-
derived mediators in acute malaria. Infect Immun. 32, 1058–1066.
(doi:10.1128/IAI.32.3.1058- 1066.1981)

Clark IA. 1982 Suggested importance of monokines in pathophysiology of endotoxin shock
and malaria. Klin Wochenschr. 60, 756–758. (doi:10.1007/ BF01716573)

Makhija R, Kingsnorth AN. 2002 Cytokine storm in acute pancreatitis. J. Hepatobiliary
Pancreat. Surg. 9, 401–410. (doi:10.1007/s005340200049)

Jahrling PB, Hensley LE, Martinez MJ, Leduc JW, Rubins KH, Relman DA, Huggins JW.
2004 Exploring the potential of variola virus infection of cynomolgus macaques as a model for
human smallpox. Proc. Natl Acad. Sci. USA 101, 15 196– 15(doi:10.1073/pnas.0405954101)

Yuen KY, Wong SS. 2005 Human infection by avian influenza A H5N1. Hong Kong Med.
J. 11, 189–199.

Ferrara JL, Abhyankar S, Gilliland DG. 1993 Cytokine storm of graft-versus-host disease:
a critical effector role for interleukin-1. Transplant Proc.

25, 1216–1217. (doi:10.1097/00007890-199312000-00045) 25. Tisoncik JR, Korth MJ,
Simmons CP, Farrar J, Martin TR, Katze MG. 2012 Into the eye of the cytokine storm.
Microbiol. Mol. Biol. Rev. 76, 16–32. (doi:10. 1128/MMBR.05015-11)
Zhao L, Cao YJ. 2019 Engineered T cell therapy for cancer in the clinic. Front. Immunol.
10, 2250–2250. (doi:10.3389/fimmu.2019.02250)

Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD,
Panoskaltsis N. 2006 Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody
TGN1412. New Engl. J. Med. 355, 1018–1028. (doi:10.1056/NEJMoa063842)

Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. 2010 The safety and side
effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9, 325–338. (doi:10.1038/nrd3003)

Honjo O, Kubo T, Sugaya F, Nishizaka T, Kato K, Hirohashi Y, Takahashi H, Torigoe T.
2019 Severe cytokine release syndrome resulting in purpura fulminans despite successful
response to nivolumab therapy in a patient with pleomorphic carcinoma of the lung: a case
report. J. ImmunoTherapy Cancer 7, 97. (doi:10.1186/s40425-019-0582-4)

Ceschi A, Noseda R, Palin K, Verhamme K. 2020 Immune checkpoint inhibitor-related
cytokine release syndrome: analysis of WHO global pharmacovigilance database. Front.
Pharmacol. 11, 557. (doi:10.3389/fphar.2020.00557)

Bakacs T, Mehrishi JN, Moss RW. 2012 Ipilimumab (Yervoy) and the TGN1412
catastrophe. Immunobiology 217, 583–589. (doi:10.1016/j.imbio. 2011.07.005)

Zhang Y et al. 2004 Analysis of serum cytokines in patients with severe acute respiratory
syndrome. Infect. Immun. 72, 4410–4415. (doi:10.1128/IAI.72. 8.4410-4415.2004)

Min CK et al. 2016 Comparative and kinetic analysis of viral shedding and immunological
responses in MERS patients representing a broad spectrum of disease severity. Sci. Rep. 6,
(doi:10.1038/ srep25359)

Rosalia RA et al. 2013 Administration of anti-CD25 mAb leads to impaired ?-
galactosylceramidemediated induction of IFN-? production in a murine model.
Immunobiology 218, 851–859. (doi:10. 1016/j.imbio.2012.10.012)

Parkin J, Cohen B. 2001 An overview of the immune system. Lancet 357, 1777–1789.
(doi:10.1016/ S0140-6736(00)04904-7)

Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, Klucher K, Staeheli P.
2008 Interferonlambda contributes to innate immunity of mice against influenza A virus but
not against hepatotropic viruses. PLoS Pathog. 4, e1000151. (doi:10.1371/journal.ppat.1000151)

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. 2020 Functional
exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol. Immunol. 17, 533–535.
(doi:10.1038/s41423-020- 0402-2)

38. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020 May
1;130(5):2202-2205. doi: 10.1172/JCI137647. PMID: 32217834; PMCID: PMC7190904.

Mahallawi WH, Khabour OF, Zhang Q, Makhdoum HM, Suliman BA. 2018 MERS-CoV
infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile.
Cytokine 104, 8–13. (doi:10.1016/j.cyto.2018.01.025)

Wong CK et al. 2004 Plasma inflammatory cytokines and chemokines in severe acute
respiratory syndrome. Clin Exp Immunol. 136, 95–103. (doi:10. 1111/j.1365-2249.2004.02415.x)

Prompetchara E, Ketloy C, Palaga T. 2020 Immune responses in COVID-19 and potential
vaccines: lessons learned from S

DOWNLOAD PDF

---

Back